By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Intellikine, Inc. 

10931 N. Torrey Pines Road
Suite 103
San Diego  California  92037  U.S.A.
Phone: 858-768-6500 Fax:


SEARCH JOBS


Industry
Biotechnology

Segment
Start Up





Company News
Takeda Pharmaceutical Co. Ltd. (TKDG.DE) to Acquire Privately-held Intellikine, Inc. for Up to $310 Million Cash 12/21/2011 6:04:59 AM
Intellikine, Inc. Earns $4 Million in Milestone Payments for Initiation of Two Phase 1 Clinical Trials for IPI-145, a Potent Inhibitor of PI3Kdelta and PI3Kgamma 10/31/2011 8:38:28 AM
Intellikine, Inc. Initiates Phase I Study of Targeted Cancer Therapeutic INK1117 10/12/2011 9:55:31 AM
Intellikine, Inc., a Leading Developer of Small Molecule Drugs Targeting the PI3K/mTOR Pathway, Names Dr. Gregory Berk Chief Medical Officer 7/12/2011 8:38:02 AM
Intellikine, Inc. and the PKD Foundation Collaborate to Advance Next-Generation Therapies for Polycystic Kidney Disease 2/10/2011 9:17:41 AM
Intellikine, Inc. and the Multiple Myeloma Research Consortium Initiate Phase I Trial of Targeted Drug INK128 11/30/2010 9:09:37 AM
Numerate and Intellikine, Inc. Conclude Research Collaboration to Discover Selective Inhibitors Against PI3 Kinase Alpha 8/11/2010 9:03:33 AM
Infinity Pharmaceuticals Inc. (INFI) and Intellikine, Inc. Enter Agreement to Develop Oral Therapies Targeting PI3 Kinase Delta, Gamma; Intellikine To Receive $13.5 Million Initially In Deal Valued Up to $488 Million 7/8/2010 7:14:25 AM
Multiple Myeloma Research Foundation (MMRF) Grants $1.0 Million Each to Intellikine, Inc. and Tragara Pharmaceuticals, Inc. to Advance Next-Generation Therapies for Multiple Myeloma 3/29/2010 1:07:43 PM
Intellikine, Inc. Appoints William Rohn to its Board of Directors 2/23/2010 8:21:07 AM
12
//-->